Moosa Khan, Ghulam Rasool Mashori, Khalid Mustafa Memon.
Safety of Losartan in hypertensive patients with thiazide induced hyperuricemia.
J Liaquat Uni Med Health Sci Jan ;7(3):163-7.

OBJECTIVE: To determine the safety of Losartan in hypertensive patients with Thiazide induced hyperuricemia. DESIGN: Randomized, open label, prospective, comparative study. SETTING: Basic Medical Sciences Institute Jinnah Postgraduate Medical Centre Karachi from February 2006 to July 2006. METHODS: Total 60 hypertensive hyperuricemic patients were enrolled in this study, selected from medical OPD of Jinnah Postgraduate Medical Centre, Karachi. Patients were divided in three groups. Group DR-1 patients were treated with Thiazide 50 mg/day, Group DR-2 with Losartan + Thiazide 50 mg/day, and Group DR-3 with Losartan 50 mg/day. The effect on serum uric acid level was measured fortnightly. RESULTS: Treatment with Thiazide + Losartan group DR-2 and Losartan group DR-3 significantly showed decrease in serum uric acid level. Whereas, Thiazide group DR-1 increased serum uric acid level. In contrast to Thiazide and Losartan + Thiazide, Losartan alone led to a greater reduction in serum uric acid level. The average percentage reduction in serum uric acid level in Thiazide + Losartan group was -12.75% and the average percentage reduction of serum uric acid level was -24.60% in Losartan group. CONCLUSION: These finding suggest that, Losartan in hypertensive hyperuricemic patients is more effective drug in lowering serum uric acid level. It may be worth pointing out that the serum uric acid level lowering effect of Losartan might be particularly useful in hyperuricemic patients those on Thiazide diuretic (for hypertension and heart failure).

PakMediNet -Pakistan's largest Database of Pakistani Medical Journals - http://www.pakmedinet.com